During drug therapy with basiliximab, the nurse monitors for signs of cytokine release syndrome, which results in a) fever, dyspnea, and general malaise.b) neurotoxicity and peripheral neuropathy.c )hepatotoxicity with jaundice.d) thrombocytopenia with increased bleeding tendencies
During drug therapy with basiliximab, the nurse monitors for signs of cytokine release syndrome, which results in
a) fever, dyspnea, and general malaise.
b) neurotoxicity and peripheral neuropathy.
c )hepatotoxicity with jaundice.
d) thrombocytopenia with increased bleeding tendencies
Basiliximab, a chimeric monoclonal antibody with a high affinity for the interleukin-2 receptor's CD25 chain, has been shown to reduce the incidence of acute rejection events in renal transplant recipients.
Basiliximab is an injectable drug that can produce an allergic reaction called cytokine release syndrome, which includes fever, dyspnea, and general malaise.
Basiliximab is not associated with neurotoxicity and peripheral neuropathy, hepatotoxicity with jaundice and thrombocytopenia with increased bleeding tendencies.
So here, the answer is option a, fever, dyspnea, and general malaise.
Step by step
Solved in 2 steps
